Syndax Pharmaceuticals Inc — Director's Dealing 2021

May 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-05-18

Reporting Person: Egros Fabrice (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-18	Common Stock	M	11926.00	$7.20	Acquired	27926.00	Direct
2021-05-18	Common Stock	M	1683.00	$7.88	Acquired	29609.00	Direct
2021-05-18	Common Stock	S	11926.00	$18.6482	Disposed	17683.00	Direct
2021-05-18	Common Stock	S	1683.00	$18.6482	Disposed	16000.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-18	Stock Options (Right to buy)	$7.88	M	1683.00	Disposed	2029-06-10	Common Stock (0.00)	Direct
2021-05-18	Stock Options (Right to buy)	$7.20	M	11926.00	Disposed	2025-08-18	Common Stock (0.00)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 93,317 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.

F2: This option is fully vested.